Biogen Idec to cut pipeline and jobs to focus on neurology
This article was originally published in Scrip
Biogen Idec has finally detailed its cost-cutting and restructuring plans after weeks of speculation. Having concluded that Biogen Idec was "a mile wide and an inch deep", CEO Dr George Scangos said neurology will be the company's main focus.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.